These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 19681692)

  • 1. 10 years' experience with the pneumococcal quinolone moxifloxacin.
    Burkhardt O; Welte T
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):645-68. PubMed ID: 19681692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin--a new fluoroquinolone antibacterial.
    Drug Ther Bull; 2004 Aug; 42(8):61-2. PubMed ID: 15310155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G; Rossi V; Salvatori E; Mirelis B
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
    Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with moxifloxacin in patients with respiratory tract infections.
    Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
    Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of Achillea clavennae essential oil against respiratory tract pathogens.
    Skocibusić M; Bezić N; Dunkić V; Radonić A
    Fitoterapia; 2004 Dec; 75(7-8):733-6. PubMed ID: 15567252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical microbiology profile of moxifloxacin.
    Krasemann C; Meyer J; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S51-63. PubMed ID: 11249830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
    Goldstein EJ; Solomkin JS; Citron DM; Alder JD
    Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
    Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R
    Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.